The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3 S,4 S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2 H-pyran-4-yl)-1,5-dihydro-4 H-pyrazolo[3,4- d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents

• Published in: Neuropharmacology Vol. 61; no. 4; pp. 665 - 676
• Main Authors: Hutson, P.H., Finger, E.N., Magliaro, B.C., Smith, S.M., Converso, A., Sanderson, P.E., Mullins, D., Hyde, L.A., Eschle, B.K., Turnbull, Z., Sloan, H., Guzzi, M., Zhang, X., Wang, A., Rindgen, D., Mazzola, R., Vivian, J.A., Eddins, D., Uslaner, J.M., Bednar, R., Gambone, C., Le-Mair, W., Marino, M.J., Sachs, N., Xu, G., Parmentier-Batteur, S.
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 2011
• Subjects: LTP; Neurite outgrowth; PDE9; Phosphodiesterase; Rodent cognition; Synaptic plasticity; Synaptic plasticity; LTP; Rodent cognition; PDE9; Neurite outgrowth; Phosphodiesterase
• ISSN: 0028-3908; 1873-7064
• DOI: 10.1016/j.neuropharm.2011.05.009

Inhibition of phosphodiesterase 9 (PDE9) has been reported to enhance rodent cognitive function and may represent a potential novel approach to improving cognitive dysfunction in Alzheimer’s disease. PF-04447943, (6-[(3 S,4 S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2 H-pyran-4-yl)-1,5-dihydro-4 H-pyrazolo[3,4- d]pyrimidin-4-one), a recently described PDE9 inhibitor, was found to have high affinity ( Ki of 2.8, 4.5 and 18 nM) for human, rhesus and rat recombinant PDE9 respectively and high selectivity for PDE9 versus PDEs1–8 and 10–11. PF-04447943 significantly increased neurite outgrowth and synapse formation (as indicated by increased synapsin 1 expression) in cultured hippocampal neurons at low (30–100 nM) but not high (300–1000 nM) concentrations. PF-04447943 significantly facilitated hippocampal slice LTP evoked by a weak tetanic stimulus at a concentration of 100 nM but failed to affect response to the weak tetanus at either 30 or 300 nM, or the LTP produced by a theta burst stimulus. Systemic administration of PF-04447943 (1–30 mg/kg p.o.) dose-dependently increased cGMP in the cerebrospinal fluid 30 min after administration indicating target engagement in the CNS of rats. PF-04447943 (1–3 mg/kg p.o.) significantly improved cognitive performance in three rodent cognition assays (mouse Y maze spatial recognition memory model of natural forgetting, mouse social recognition memory model of natural forgetting and rat novel object recognition with a scopolamine deficit). When administered at a dose of 3 mg/kg p.o., which improved performance in novel object recognition, PF-04447943 significantly increased phosphorylated but not total GluR1 expression in rat hippocampal membranes. Collectively these data indicate that PF-04447943 is a potent, selective brain penetrant PDE9 inhibitor that increased indicators of hippocampal synaptic plasticity and improved cognitive function in a variety of cognition models in both rats and mice. Results with PF-04447943 are consistent with previously published findings using a structurally diverse PDE9 inhibitor, BAY73-6199, and further support the suggestion that PDE9 inhibition may represent a novel approach to the palliative remediation of cognitive dysfunction. ► PF-04447943 is a potent, selective, brain penetrant PDE9 inhibitor. ► PF-04447943 increased markers of hippocampal synaptic plasticity. ► PF-04447943 facilitated hippocampal LTP in vitro. ► PF-04447943 improved function in three different rodent cognition assays.